Posted on

cbd warnings

Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.

Cbd warnings

The five companies were Bee Delightful, which sells Canna Bees Rescue Blend; G&L Wellness, LLC, which sells C Better Daily eye drop products for humans and pets; New Leaf Pharmaceuticals, LLC, which sells Rhinodol CBD intranasal products; NextL3evel Services Group, LLC doing business as This Stuff Is Good For You, which sells CBD products for humans and pets; and Wellness BioSciences RX, which sells inhalers, soft gels, oil drops and balm that contain CBD.

G&L Wellness claimed its eye drop products were anti-inflammatory and anti-bacterial. New Leaf Pharmaceuticals claimed CBD could help with post-traumatic stress disorders (PTSD) and rheumatoid arthritis.

The FDA pointed to Bee Delightful’s claims for honey as well as CBD. Bee Delightful claimed honey kills unwanted bacteria and fungus, helps with digestive issues, and soothes a sore throat. The company’s CBD claims included may reduce pain from diseases like multiple sclerosis and rheumatoid arthritis, may reduce anxiety and depression, may alleviate cancer treatment symptoms, may reduce acne, and may benefit heart health.

“We remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety,” said Amy Abernethy, MD, PhD, principal deputy commissioner for the FDA. “Meanwhile, we will continue to monitor and take action, as needed, against companies that unlawfully market their products — prioritizing those that pose the greatest risk of harm to the public.”